14
Phase 2–4 trials
Lipid & Lp(a) therapies · Live ClinicalTrials.gov data
Obicetrapib clinical trial pipeline
ClinicalTrials.gov lists 14 phase 2–4 trials for obicetrapib, 4 of them actively recruiting. The next phase 3 primary completion among them is expected Nov 2026. Refreshed daily — add up to four competitors to compare pipelines side by side.
7
Phase 3 trials
4
Actively recruiting
Nov 2026
Next phase 3 primary completion
14,493
Participants across trials
NewAmsterdam Pharma
Lead sponsor by trial count
obicetrapib (14)6 active2021–2029
obicetrapib
'21
'22
'23
'24
'25
'26
'27
'28
'29
obicetrapib
ROSEP2
OCEANP2
BROADWAYP3
Proof-of-concept, Open-label Study in Patients With Early Alzheimer's DiseaseP2
PREVAILP3
ROSE2P2
A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.P2
BROOKLYNP3
TANDEMP3
REMBRANDTP3
VINCENTP2
VERMEERP2
RUBENSP3
MEDICIP3
Upcoming readouts
6 ahead · obicetrapib
Select a trial to load its full ClinicalTrials.gov record.
Key obicetrapib trials
Top 12 of the 14 registered phase 2–4 trials, ordered by phase and status. Each links to its full ClinicalTrials.gov record.
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07614958 | MEDICI — Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat… | Phase 3 | Recruiting | Jan 2027 |
| NCT07219602 | RUBENS — A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Dail… | Phase 3 | Recruiting | Mar 2028 |
| NCT05202509 | PREVAIL — Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease | Phase 3 | Active, not recruiting | Nov 2026 |
| NCT06305559 | REMBRANDT — A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque | Phase 3 | Active, not recruiting | Nov 2027 |
| NCT05425745 | BROOKLYN — Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies… | Phase 3 | Completed | May 2024 |
| NCT06005597 | TANDEM — Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies | Phase 3 | Completed | Sept 2024 |
| NCT05142722 | BROADWAY — Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies | Phase 3 | Completed | Sept 2024 |
| NCT06982508 | VERMEER — Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers | Phase 2 | Recruiting | Sept 2026 |
| NCT06496243 | VINCENT — Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels | Phase 2 | Recruiting | Nov 2026 |
| NCT04770389 | OCEAN — Randomized Study of Obicetrapib in Combination With Ezetimibe | Phase 2 | Completed | May 2021 |
| NCT04753606 | ROSE — Randomized Study of Obicetrapib as an Adjunct to Statin Therapy | Phase 2 | Completed | May 2021 |
| NCT05266586 | ROSE2 — Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy | Phase 2 | Completed | Aug 2022 |
Related drug pipelines
FAQ
- How many clinical trials are running for obicetrapib?
- ClinicalTrials.gov currently lists 14 phase 2–4 obicetrapib trials: 7 phase 2, 7 phase 3, and 0 phase 4. 4 are actively recruiting.
- Where does this data come from?
- All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.
- Can I compare obicetrapib against other drugs?
- Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.
Join the waitlist
Be the first to access ComplyRx
We'll let you know as soon as your spot opens to use ComplyRx.
By joining, you agree to our Privacy Policy.